Información del artículo
El Texto completo está disponible en PDF
Bibliogrífia
[1.]
E.B. Keeffe, F.B. Hollinger.
Therapy of hepatitis C: consensus interferon trials. Consensus Interferon Study Group.
Hepatology, 26 (1997), pp. 101-107
[2.]
W.M. Lee, K.R. Reddy, M.J. Tong, M. Black, D.J. Van Leeuwen, F.B. Hollinger, et al.
The Consensus Interferon Study Group.
Early hepatitis C virus-RNA responses predict interferon treatment outcomes in chronic. hepatitis C. Hepatology, 28 (1998), pp. 1411-1415
[3.]
L. Chemello, L. Cavalletto, F. Noventa, P. Bonetti, C. Casarin, E. Bernardinello, et al.
Predictors of sustained response, relapse and no response in patients with chronic hepatitis C treated with interferon-alpha.
J Viral Hepat, 2 (1995), pp. 91-96
[4.]
J.G. McHutchison, S.C. Gordon, E.R. Schiff, M.L. Shiffman, W.M. Lee, V.K. Rustgi, et al.
Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.
N Engl J Med, 339 (1998), pp. 1485-1492
[5.]
T. Poynard, P. Marcellin, S.S. Lee, C. Niederau, G.S. Minuk, G. Ideo, et al.
Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT).
Lancet, 352 (1998), pp. 1426-1432
[6.]
G.L. Davis, R. Esteban-Mur, V. Rustgi, J. Hoefs, S.C. Gordon, C. Trepo, et al.
Recombinant interferon alfa-2b alone or in combination with ribavirin for retreatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group.
N Engl J Med, 339 (1998), pp. 1493-1499
[7.]
J.A. Moreno-Monteagudo, A. Castro, A. De Pedro, J.A. Lorenzo, M. Fernández-Bermejo, S. López, et al.
Interferon alpha plus ribavirin treatment for 12 months increases the sustained response rates in chronic hepatitis C relapser patients [en prensa].
Aliment Pharmacol Ther, 16 (2002), pp. 243-249
[8.]
S. Zeuzem, S.V. Feinman, J. Rasenack, E.J. Heathcote, M.Y. Lai, E. Gane, et al.
Peginterferon alfa-2a in patients with chronic hepatitis C.
N Engl J Med, 343 (2000), pp. 1666-1672
[9.]
E.J. Heathcote, M.L. Shiffman, W.G. Cooksley, G.M. Dusheiko, S.S. Lee, L. Balart, et al.
Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis.
N Engl J Med, 343 (2000), pp. 1673-1680
[10.]
M.P. Manns, J.G. McHutchison, S.C. Gordon, V.K. Rustgi, M. Shiffman, R. Reindollar, et al.
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.
Lancet, 358 (2001), pp. 958-965
[11.]
K.R. Reddy, T.L. Wright, P.J. Pockros, M. Shiffman, G. Everson, R. Reindollar, et al.
Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C.
Hepatology, 33 (2001), pp. 433-438
[12.]
K.L. Lindsay, C. Trepo, T. Heintges, M.L. Shiffman, S.C. Gordon, J.C. Hoefs, et al.
A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis. The Hepatitis Interventional Therapy Group.
Hepatology, 34 (2001), pp. 395-403
[13.]
S. Zeuzem.
Treatment of chronic hepatitis C virus infection in patients with cirrhosis.
J Viral Hepat, 7 (2000), pp. 327-334
[14.]
J.A. Moreno-Monteagudo, L. García-Buey, R. Moreno-Otero.
Tratamiento de la hepatitis crónica C en pacientes no respondedores al interferón.
Gastroenterol Hepatol, 23 (2000), pp. 1-6
[15.]
P. Andreone, C. Cursaro, A. Gramenzi, S. Fiorino, L. Di Giammarino, R. Miniero, et al.
Interferon alpha plus ketoprofen or interferon alpha plus ribavirin in chronic hepatitis C non-responder to interferon alpha alone: results of a pilot study.
Ital J Gastroenterol Hepatol, 31 (1999), pp. 688-694
[16.]
A. Tsubota, H. Kumada, Y. Arase, K. Chayama, S. Saitoh, K. Ikeda, et al.
Combined ursodeoxycholic acid and glycyrrhizin therapy for chronic hepatitis C virus infection: a randomized controlled trial in 170 patients.
Eur J Gastroenterol Hepatol, 11 (1999), pp. 1077-1083
[17.]
T.L. Fong, S.H. Han, N.C. Tsai, T.R. Morgan, M. Mizokami, D. Qian, et al.
A pilot randomized, controlled trial of the effect of iron depletion on long-term response to alpha-interferon in patients with chronic hepatitis C.
J Hepatol, 28 (1998), pp. 369-374
[18.]
A. Alberti, L. Chemello, F. Noventa, L. Cavalletto, G. De Salvo.
Therapy of hepatitis C: re-treatment with alpha interferon.
Hepatology, 26 (1997), pp. 137-142
[19.]
J.L. Patterson, R. Fernández-Larsson.
Molecular mechanisms of action of ribavirin.
Rev Infect Dis, 12 (1990), pp. 1139-1146
[20.]
R.C. Tam, B. Pai, J. Bard, C. Lim, D.R. Averett, U.T. Phan, et al.
Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile.
J Hepatol, 30 (1999), pp. 376-382
[21.]
R. Sostegni, V. Ghisetti, F. Pittaluga, G. Marchiaro, G. Rocca, E. Borghesio, et al.
Sequential versus concomitant administration of ribavirin and interferon alfa-n3 in patients with chronic hepatitis C not responding to interferon alone: results of a randomized, controlled trial.
Hepatology, 28 (1998), pp. 341-346
[22.]
P. Andreone, A. Gramenzi, C. Cursaro, G. Sbolli, S. Fiorino, L. Di Giammarino, et al.
Interferon-alpha plus ribavirin in chronic hepatitis C resistant to previous interferon-alpha course: results of a randomized multicenter trial.
J Hepatol, 30 (1999), pp. 788-793
[23.]
G. Barbaro, G. Di Lorenzo, G. Belloni, L. Ferrari, A. Paiano, P. Del Poggio, et al.
Interferon alpha-2b and ribavirin in combination for patients with chronic hepatitis C who failed to respond to. or relapsed after, interferon alpha therapy: a randomized trial.
Am J Med, 107 (1999), pp. 112-118
[24.]
H. Bell, K. Hellum, S. Harthug, B. Myrvang, S. Ritland, A. Maeland, et al.
Treatment with interferon alpha-2a alone or interferonalpha-2a plus ribavirin in patients with chronic hepatitis C previously treated with interferon alpha-2a. CONSTRUCT Group.
Scand J Gastroenterol, 34 (1999), pp. 194-198
[25.]
M. Milella, T. Santantonio, G. Pietromatera, R. Maselli, C. Casalino, N. Mariano, et al.
Retreatment of non-responder or relapser chronic hepatitis C patients with interferon plus ribavirin vs interferon alone.
Ital J Gastroenterol Hepatol, 31 (1999), pp. 211-215
[26.]
M.L. Shiffman, C.M. Hofmann, J. Gabbay, V.A. Luketic, R.K. Sterling, A.J. Sanyal, et al.
Treatment of chronic hepatitis C in patients who failed interferon monotherapy: effects of higher doses of interferon and ribavirin combination therapy. The Virginia Cooperative Hepatitis Treatment Group.
Am J Gastroenterol, 95 (2000), pp. 2928-2935
[27.]
G. Bresci, G. Parisi, M. Bertoni, F. Scatena, A. Capria.
Interferon plus ribavirin in chronic hepatitis C non-responders to recombinant alpha-interferon.
J Viral Hepat, 7 (2000), pp. 75-78
[28.]
A. Tromm, I. Greving, T. Griga, K. Mankel, D. Huppe.
Interferonalpha- 2b + ribavirin for the treatment of chronic hepatitis C in non-responders to interferon-alpha-monotherapy.
Z Gastroenterol, 38 (2000), pp. 159-164
[29.]
L. Cavalletto, L. Chemello, C. Donada, P. Casarin, F. Belussi, E. Bernardinello, et al.
The pattern of response to interferon alpha (alpha-IFN) predicts sustained response to a 6-month alpha-IFN and ribavirin retreatment for chronic hepatitis C. TVVH Study Group.
J Hepatol, 33 (2000), pp. 128-134
[30.]
F. Hasan, H. Asker, M. Al Shamali, M. Al Kalaoui, B. Al Nakib.
Interferon-alpha plus ribavirin combination therapy for the treatment of chronic hepatitis C in interferon non-responders.
Hepatogastroenterology, 47 (2000), pp. 1642-1644
[31.]
J. Enríquez, A. Gallego, X. Torras, T. Pérez-Olmeda, M. Diago, V. Soriano, et al.
Retreatment for 24 vs 48 weeks with interferon- alpha 2b plus ribavirin of chronic hepatitis C patients who relapsed or did not respond to interferon alone.
J Viral Hepat, 7 (2000), pp. 403-408
[32.]
Z.M. Younossi, K.D. Mullen, W. Zakko, S. Hodnick, E. Brand, D.S. Barnes, et al.
A randomized, double-blind controlled trial of interferon alpha-2b and ribavirin vs interferon alpha-2b and amantadine for treatment of chronic hepatitis C non-responder to interferon monotherapy.
J Hepatol, 34 (2001), pp. 128-133
[33.]
R. Cozzolongo, R. Cuppone, V. Giannuzzi, L. Amati, L. Caradonna, V. Tamborrino, et al.
Combination therapy with ribavirin and alpha interferon for the treatment of chronic hepatitis C refractory to interferon.
Aliment Pharmacol Ther, 15 (2001), pp. 129-135
[34.]
B. Kallinowski, H. Liehr, B. Moeller, W. Stremmel, J.G. Wechsler, M. Wiese, et al.
Combination therapy with interferon-alpha 2b and ribavirin for the treatment of relapse patients and non-responders with chronic HCV infection.
Z Gastroenterol, 39 (2001), pp. 199-204
[35.]
P. Ferenci, R. Stauber, P. Steindl-Munda, M. Gschwantler, P. Fickert, C. Datz, et al.
Treatment of patients with chronic hepatitis C not responding to interferon with high-dose interferon alpha with or without ribavirin: final results of a prospective randomized trial. Austrian Hepatitis Study Group.
Eur J Gastroenterol Hepatol, 13 (2001), pp. 699-705
[36.]
G. Barbaro, G. Di Lorenzo, M. Soldini, G. Giancaspro, A. Pellicelli, B. Grisorio, et al.
Intravenous recombinant interferon-beta versus interferon-alpha-2b and ribavirin in combination for short-term treatment of chronic hepatitis C patients not responding to interferon-alpha. Multicenter Interferon Beta Italian Group Investigators.
Scand J Gastroenterol, 34 (1999), pp. 928-933
[37.]
O. Lo Iacono, A. Castro, M. Diago, J.A. Moreno-Monteagudo, M. Fernández-Bermejo, P. Vega, et al.
Interferon alfa-2b plus ribavirin for chronic hepatitis C patients who have not responded to interferon monotherapy.
Aliment Pharmacol Ther, 14 (2000), pp. 463-469
[38.]
M. Diago, M. Luján, D. Valeros, C. Tuset, G. Marcaida, V. García, et al.
Long-term response to interferon plus ribavirin in patients with chronic hepatitis C refractory to interferon.
Rev Esp Enferm Dig, 93 (2001), pp. 353-363
[39.]
V. Di Marco, A. Vaccaro, D. Ferraro, G. Alaimo, V. Rodolico, P. Parisi, et al.
High-dose prolonged combination therapy in nonresponders to interferon monotherapy for chronic hepatitis C.
Aliment Pharmacol Ther, 15 (2001), pp. 953-958
[40.]
J.A. Moreno-Monteagudo, L. García-Buey, M. Fernández-Bermejo, P. Sanz, M.J. Borque, O. Lo Iacono, et al.
Effectiveness of interferon (IFN) plus ribavirin (RBV) in IFN non-responder patients with chronic hepatitis C (CHC) [abstract].
J Hepatol, 30 (1999), pp. 230
[41.]
S.W. Schalm, B.E. Hansen, L. Chemello, A. Bellobuono, J.T. Brouwer, O. Weiland, et al.
Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Metaanalysis of individual patient data from European centers.
J Hepatol, 26 (1997), pp. 961-966
[42.]
J.A. Moreno-Monteagudo, M. Fernández-Bermejo, L. García-Buey, P. Sanz, O. Lo Iacono, C. García-Monzón, et al.
Interferon alpha with ribavirin for the treatment of chronic hepatitis C in nonresponders or relapsers to interferon monotherapy.
Aliment Pharmacol Ther, 12 (1998), pp. 717-723
[43.]
G. Bresci, G. Parisi, M. Bertoni, A. Capria.
High-dose interferon plus ribavirin in chronic hepatitis C not responding to recombinant alpha-interferon.
Dig Liver Dis, 32 (2000), pp. 703-707
[44.]
R.S. Koff.
Cost-effectiveness of treatment for chronic hepatitis C.
J Hepatol, 31 (1999), pp. 255-258
[45.]
J.P. Smith.
Treatment of chronic hepatitis C with amantadine.
Dig Dis Sci, 42 (1997), pp. 1681-1687
[46.]
M. Tabone, E. Ercole, C. Zaffino, F. Sallio Bruno, A. Pera, F. Bonino, et al.
Amantadine hydrochloride decreases serum ALT activity without effects on serum HCV-RNA in chronic hepatitis C patients.
Ital J Gastroenterol Hepatol, 30 (1998), pp. 611-613
[47.]
M.B. Parolin, M.A. Lacerda, R.W. Lopes.
Amantadine-HCL in the treatment of chronic hepatitis C in non-responders to alpha-interferon. Effect on ALT serum levels and viral load.
Arq Gastroenterol, 36 (1999), pp. 63-67
[48.]
M. Khalili, C.B. Denham, R.P. Perrillo.
Interferon and ribavirin versus interferon and amantadine in interferon nonresponders with chronic hepatitis C.
Am J Gastroenterol, 95 (2000), pp. 1122-1124
[49.]
G.B. Gaeta, G. Stornaiuolo, M. Stanzione, T. Ascione, C. Pasquazzi, G. Taliani, et al.
Interferon-alpha plus amantadine in chronic hepatitis C resistant to interferon alone: a pilot randomized study.
J Viral Hepat, 8 (2001), pp. 284-286
[50.]
G. Teuber, T. Berg, U. Naumann, J. Raedle, S. Brinkmann, U. Hopf, et al.
Randomized, placebo-controlled, double-blind trial with interferon-alpha with and without amantadine sulphate in primary interferon-alpha nonresponders with chronic hepatitis C.
J Viral Hepat, 8 (2001), pp. 276-283
[51.]
S. Brillanti, M. Foli, M. Di Tomaso, L. Gramantieri, C. Masci, L. Bolondi.
Pilot study of triple antiviral therapy for chronic hepatitis C in interferon alpha non-responders.
Ital J Gastroenterol Hepatol, 31 (1999), pp. 130-134
[52.]
T. Carlsson, K. Lindahl, R. Schvarcz, R. Wejstal, I. Uhnoo, S. Shev, et al.
HCV RNA levels during therapy with amantadine in addition to interferon and ribavirin in chronic hepatitis C patients with previous nonresponse or response/relapse to interferon and ribavirin.
J Viral Hepat, 7 (2000), pp. 409-413
[53.]
T. Berg, U. Naumann, B. Wiedenmann, U. Hopf.
Pilot study of interferon-alpha high-dose induction therapy in combination with ribavirin plus amantadine for nonresponder patients with chronic hepatitis C.
Z Gastroenterol, 39 (2001), pp. 145-151
[54.]
S. Brillanti, F. Levantesi, L. Masi, M. Foli, L. Bolondi.
Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C.
Hepatology, 33 (2001), pp. 1014-1015
[55.]
T.L. Fong, M.W. Fried, J. Clarke Platt.
A pilot study of rimantadine for patients with chronic hepatitis C unresponsive to interferon therapy.
Am J Gastroenterol, 94 (1999), pp. 990-993
Copyright © 2002. Elsevier España, S.L.. Todos los derechos reservados
